[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vegfr-tki\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vegfr-tki":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100602541","prospective-national-cohort-evaluating-prognostic-factors-for-efficacy-of-fruquintinib-treatment-in-patients-with-metastatic-colorectal-cancer-100602541",false,"NCT07124858","Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer","PRODIGE 108 - COHORTE 2320 - COFRUQ Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer","COFRUQ","Inclusion Criteria:\n\n* Patients aged 18 and over.\n* Histologically confirmed colorectal adenocarcinoma with locally advanced disease and\u002For unresectable metastasis(es) receiving treatment with fruquintinib under i) compassionate\u002Fearly access and ii) marketing authorisation and reimbursement in France.\n* Obtain informed consent from the patient for the clinical-biological cohort.\n* Agreement to take biological samples of ctDNA and send tumour blocks (patient participation in the pharmacokinetic study remains optional).\n\nExclusion Criteria:\n\n* Patient with another concurrent cancer at the time of diagnosis, requiring systemic treatment or influencing prognosis (in the opinion of the centre's medical team).\n* Contraindication due to psychological or social reasons that may hinder follow-up (cognitive deficit, psychological disorders incompatible with obtaining consent; inability to be followed in the same centre throughout the follow-up period for geographical reasons).\n* Pregnant or breast-feeding women.\n* Patients under court protection or subject to a protective measure (patient under guardianship or curatorship).","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer.",[27,28,29],"Metastatic Colorectal Cancer (CRC)","Antineoplastic Agents, Immunological","VEGFR-TKI",[31,32,33],"Metastatic colorectal cancer","Fruquintinib","cohort","RECRUITING","2026-05-22",{"date":37,"type":38},"2026-05-26","ACTUAL",{"date":40,"type":38},"2026-03-10",{"date":42,"type":21},"2031-12-31",{"name":44,"class":45},"Federation Francophone de Cancerologie Digestive","OTHER",83]